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a b s t r a c t
Multiple sclerosis (MS) is a progressive disease of the central nervous system. It is charac-
terized by disseminated foci of demyelination, which are responsible for the diverse clinical
picture of MS. Pain is a frequent but underestimated symptom of multiple sclerosis. It is
estimated to affect 29–86% of MS patients in various stages of the disease and severely
inﬂuences rehabilitation and quality of life. The pain experienced by MS patients is generally
caused by nervous system damage during the course of the disease process and can usually
be characterized as central neuropathic pain (less frequently as peripheral or nociceptive
pain). The most frequent symptoms include dysesthetic extremity pain, painful tonic
spasms, Lhermitte's sign, trigeminal neuralgia, headaches and low back pain. This paper
discusses the probable mechanisms behind the development of pain in MS, the prevalence,
classiﬁcation, types of pain, as well as the most effective treatment methods.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Multiple sclerosis is a progressive, inﬂammatory demyelinat-
ing disease of the central nervous system (CNS) of an unknown
etiology [1]. Its prominent feature is the presence of dissemi-
nated foci of demyelination, mainly in the white matter; in
most cases, demyelination occurs periventricularly. The
complex pathomechanism of the disease and its disseminated
nature make both the clinical picture and the course of MS
exceptionally diverse. The symptoms include movement,
visual and sensory disturbances, cerebellar symptoms and* Corresponding author at: Oddział Neurologii, Szpital Specjalistyczny
Tel.: +48 041 3902259/601313415; fax: +48 041 3902364.
E-mail addresses: wbrola@wp.pl, wbrola@gmail.com (W. Brola).
http://dx.doi.org/10.1016/j.pjnns.2014.07.009
0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Usphincter control disturbances [1]. Pain is a frequent yet
underestimated symptom of multiple sclerosis. For years,
multiple sclerosis was thought of as a painless condition;
however, as early as 1872, Charcot described pains in the
shoulder and pelvic girdle region accompanying the disease
[2]. In 1924, Lhermitte described the phenomenon of an
electrical-like sensation running down the back, which is
characteristic of MS [1–3]. However, the theory of a painless
course of multiple sclerosis was only deﬁnitively invalidated at
the close of the XX century. Recently, pain has been recognized
as a factor that signiﬁcantly affects quality of life [3–5]. The
study conducted by Warnell [6] showed that among MS im. Św. Łukasza, ul. Gimnazjalna 41B, 26-200 Końskie, Poland.
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difﬁculty working, 44% had difﬁculty sleeping and 34%
reported troubled interpersonal relationships [6].
2. Prevalence of pain
Pain is rarely observed at the initial stages of MS and is
estimated to be its ﬁrst symptom in only 1% of patients [3,7,8].
However, it frequently accompanies the advanced stages,
being a nagging symptom that severely limits the patient's
functioning, treatment and rehabilitation. Pain is estimated to
occur in approximately 29–86% of patients at different stages
of MS [3,8–12]. Pain present in the month preceding the
evaluation was diagnosed in 53–79% of patients, whereas pain
during the evaluation was present in 43–54% [5,8–11]. In 15% of
patients, pain is acute (usually paroxysmal), but it is chronic in
the straight majority [6,7,10]. Kalia et al. and Khan et al.
estimated that chronic pain is present in 64–69% of MS patients
[4,11]. According to the majority of authors, central pain is the
most frequent type of pain [3,9–12]. In Osterberg's study, this
type of pain was reported by 27.5% of patients [12]. However,
Svendsen et al. reported that muscular (39.6% of patients) and
articular pain (41.9%) are among the most frequent pain
symptoms [5].
In a Polish study, Fryze et al. diagnosed various types of
pain in 70.2% of MS patients [2]. In 8% of these patients, it was
their ﬁrst symptom of multiple sclerosis. The most frequently
occurring symptoms were dysesthetic extremity pain (45%),
back pain (34%) and painful tonic spasms (22%). Chronic pain
was diagnosed in 60% of patients [2]. On the other hand,
Kwolek et al. found various types of pain in 83% of patients
(mainly painful muscle spasms and painful paresthesia) [13].
This large discrepancy in the results stems from the
different deﬁnitions of pain that were adopted in the studies,
different methods of pain assessment, and the different stages
of disease progression and disability in the studied popula-
tions. It is usually assumed that pain affects approximately
half of MS patients, and all studies conﬁrm that it is more
frequent in people with multiple sclerosis than in those who
are not affected by the disease [3,7–13].
The frequency of pain increases with the progression of MS
and may be the dominating syndrome in its advanced stages.
However, it should be noted that pain may occur at all stages
of MS, and it is reported by as many as 11–23% of
newly diagnosed patients [4,9–11]. Risk factors for pain in
MS include older age, female gender (F/M = 2.2/1), longer
duration of illness, higher EDSS score, concomitant depression
or mental disorders, unstable course of illness, lower educa-
tion and primarily- or secondarily-progressing type of MS
[3,4,8,12,14].
3. Pathophysiology of pain in patients with
multiple sclerosis
It is believed that most MS-related pain symptoms are of a
neuropathic central type [3,8,15,16]. Neuropathic pain caused
by peripheral nervous system damage, nociceptive pain
caused by irritation of peripheral nerve endings in thenociceptive system and psychogenic pain are less frequent
[3,15,16].
Central pain results from a primary CNS injury, but its
pathomechanism has not yet been fully elucidated. The
demyelination and axonal damage in the brain and spinal
cord lead to distinct mechanisms and central hyperexcitability
[14–16]. The pain is associated with damage of the thalamus or
the parietal cortex, in which projection areas for the sensory
tract are located, and it is usually secondary to lesions in the
spino-thalamo-cortical pathways [23].
It is postulated that the lack of normal afferent impulses in
the area of the lesion causes quantitative and qualitative
changes in sodium and calcium channels, which increase
neuronal excitability [8,14–17]. The pain symptoms are
thought to result from the ephaptic spread of spontaneous
ectopic discharges generated by demyelinated axons. Conse-
quently, the spinal cord is constantly inundated with false
information about painful stimuli, which in fact are non-
existent [17]. The CNS has demonstrated the ability to modify
its functions, which causes an enormous variety of pain
symptoms depending on the time and place of their occur-
rence, pathological processes, individual variability, age and
many other factors [17,18]. One of the most important roles in
these processes is played by NMDA (N-methyl-D-aspartate)
receptors for excitatory amino acids and NK-1 neurokinin
receptors situated postsynaptically in the posterior horns of
the spinal cord [27]. There is evidence that NMDA receptors
take part in triggering the long-term excessive pain response
to a slight, repetitive irritating impulse, due to the 'wind-up'
effect [15–18]. This phenomenon is similar to the kindling
effect observed in epileptic foci and is responsible for the
creation of abnormal discharges [16,17]. An increased calcium
ion concentration in cells leads to a rise of enzymatic activity.
This result, for example, in the enhanced synthesis of nitrogen
oxide, which takes part in the neuropathic pain mechanisms,
most likely via an intensiﬁed release of neurotransmitters
from presynaptic terminals [18,27].
Central pain involves large areas such as the whole side of
the body and is usually one-sided. It is not associated with
movement disturbances but may be aggravated by external
stimuli. It is characterized by acute, burning or stinging
sensations, sensory disturbances and poor (or no) response to
standard analgesic therapy [8,18]. Central pain usually lasts for
a short time and may take the form of a seizure. However, it
may also be chronic with recurring relapses. It is usually
moderate in intensity but can aggravate signiﬁcantly during
the attacks and in response to heat, cold or touch. In almost all
cases, the pain is associated with other symptoms of CNS
damage such as sensory disturbances, paresis or ataxia
[8,17,18]. Central pain includes psychogenic and overlapping
pain [8].
Peripheral neuropathic pain is less frequent in multiple
sclerosis. In most patients, it manifests itself as a chronic,
searing, burning pain of a dysesthetic type (unpleasant
sensation arising spontaneously or following a stimulus) or
as a paroxysmal pain that is usually severe, short-lasting,
stinging and ‘‘electric-like’’ [16]. Its onset is spontaneous and
may be triggered by movement. It is frequently accompanied
by mechanical or thermal allodynia (pain in response to
touch or hot/cold temperature), hyperalgesia (increased
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mildly painful stimulus with delayed effect, radiating
outside the damaged nerve and lasting longer than the
stimulus), hypoalgesia (a decreased sensitivity to painful
stimuli) [17–19].
Muscular and articular pain may be associated with
musculoskeletal complains. It is usually nociceptive but
may also result from central pain. Some types of MS-related
chronic pain may not be ascribed to any of the categories
above. Headache in patients with MS is a prevalent example of
this type of pain condition, which involves a complex mixture
of neuropathic, inﬂammatory and musculoskeletal mecha-
nisms [3].
4. Classiﬁcation and types of pain
The literature provides different classiﬁcations of pain types in
multiple sclerosis. They are usually divided into primary and
secondary pain syndromes. The primary types of pain are
directly associated with the disease and its pathology (painful
tonic spasms in the extremities, Lhermitte's sign, trigeminal
neuralgia, glossopharyngeal neuralgia). Secondary syndromes
result from the already-existing symptoms of the disease
(radiculalgia and low back pain are secondary to faulty posture
and gait disturbances due to limb paresis or other movement
disturbances) [1].
With regard to duration, pain syndromes are divided into
acute and chronic [3,12,18]. It is postulated that most types of
acute pain syndromes are associated with the essence of the
disease, while their pathophysiology is associated with lesions
located in the pons, brainstem and the nerve itself. Such
syndromes include paroxysmal burning pain of the lower
extremities, painful tonic spasms of extremities and Lher-
mitte's sign. Chronic syndromes include painful lower limb
dysesthesia and back pain.
The World Health Organisation (WHO) distinguishes three
types of pain occurring in MS: neuropathic, somatic and
psychogenic [20].
In 2008, O'Connor et al. [3] suggested the most widely used
classiﬁcation of pain according to its pathophysiology (Table 1).
In 2013, Truini et al. proposed a new mechanism-based
classiﬁcation of pain associated with MS (Table 2) [21].Table 1 – Classification of pain conditions associated with
multiple sclerosis (adapted from O'Connor et al. [3]).
Pain classiﬁcation Examples
Continuous central
neuropathic pain
Dysesthetic lower
extremity pain
Intermittent central
neuropathic pain
Trigeminal neuralgia
Lhermitte's sign
Musculoskeletal pain Lower back pain
Muscle spasms
Painful tonic spasms
Mixed neuropathic
and non-neuropathic
pain
Headache5. Painful dysesthesias (dysesthetic extremity
pain)
Painful dysesthesias belong to the category of continuous
central neuropathic pain and usually affect the lower
extremities; however, they may also involve the trunk, upper
extremities or head. In a study by Osterberg, 87% of
dysesthesias were located in lower and 31% in upper
extremities. They were more frequent in patients with the
primary progressive type of MS, mostly bilateral (76%), with
88% occurring during the day [12]. Only 2% of patients
complained of paroxysmal pain. The pain was intense with
small to moderate spontaneous variation [12].
Painful dysesthesia is the most frequent type of pain
occurring in MS [5,7,10]. Its prevalence is estimated at 17–26%
[3,9,10]. Fryze et al. found this type of pain in 45% of patients
[2]. Painful dysesthesias are described by patients as a
‘‘continuous burning pain’’ (searing, burning, tingling, pierc-
ing, ‘‘electric-like’’), which worsens with exposure to heat or
weather changes [5,7]. Allodynia and hyperalgesia are typical
as well.
This type of pain is typically bilateral, affecting the legs and
feet; it is usually worse at night and can be exacerbated by
physical activity [3–5]. It must be distinguished from other
conditions that could cause bilateral extremity pain, including
musculoskeletal pain and pain associated with peripheral
neuropathy [3,5–7].
Because painful dysesthesias are a type of neuropathic
central pain, antiepileptic and antidepressant drugs are
administered. The recommended ﬁrst-line treatments include
amitriptyline and other tricyclic antidepressants, as well as
gabapentin and pregabalin [22–27]. Among all antidepressant
drugs, the tricyclic antidepressants and especially amitripty-
line, play the most crucial role. If amitriptyline causes some
adverse effects, nortriptyline should be used [22,23]. In
addition, some new generation antidepressant drugs (selec-
tive serotonin-reuptake inhibitors, SSRI) show efﬁciency
comparable to the performance of classical antidepressants,
with the added beneﬁt of a lower rate of side effects [23–27].
The best therapeutic results have been observed for duloxetine
and venlafaxine [28]. The antiepileptic drugs used so far, such
as carbamazepine and valproic acid or phenytoin, are
currently believed to be less efﬁcient than the new generation
drugs. Most studies are aimed at assessing the effectiveness of
gabapentin and pregabalin [22–28]. Lamotrigine and topira-
mate may also be effective [22–28]. If antidepressant and
antiepileptic drugs do not bring about satisfactory results in
the treatment of central pain, the European Federation of
Neurological Societies (EFNS) recommends starting opioids.
However, none of the studies conﬁrmed their effectiveness in
the treatment of pain in multiple sclerosis [28]. A positive
effect was observed for cannabinoids, as evaluated in several
randomized controlled trials [29–31]. Most of the studies
conﬁrmed the effectiveness of these drugs in relieving chronic
and paroxysmal pain, especially in painful dysesthesias.
However, it should be borne in mind that the primary endpoint
of these studies was the evaluation of spasticity [29–31].
Cannabinoids are currently recommended as a second-line
treatment in some cases of treatment-resistant pain. When
Table 2 – Mechanism-based classification of pain in multiple sclerosis (according to Truini et al. [21]).
Types of pain Possible mechanisms
Neuropathic pains
Dysesthetic extremity pain Deafferentation pain secondary to lesions in the spino-thalamo-cortical pathways
Trigeminal neuralgia Paroxysmal high-frequency discharges ectopically generated by intra-axial inﬂammatory
demyelination and extra-axial mechanical demyelination of the trigeminal primary
afferents
Lhermitte's phenomenon Paroxysmal neuropathic pain due to high-frequency ectopic impulse generated by
demyelination of the dorsal column primary afferents
Nociceptive pains
Pain associated with optic neuritis Nerve trunk pain originating from endoneural inﬂammation intraneural nociceptors of
the nervi nervorum
Musculoskeletal pains Nociceptive pain related to postural abnormalities secondary to motor disturbances
Back pain Consequence of postural anomalies
Migraine Nociceptive pain favored by predisposing factors or secondary to midbrain/periaqueductal
grey matter lesions
Tension-type headache Probably coexisting conditions
Treatment-induced pains Interferon beta (ﬂu-like symptoms, myalgias, and headache)
Glatiramer acetate (pain at the injection site)
Corticosteroids (osteoporosis and secondary pain)
Mixed pains
Painful tonic spasms High-frequency discharges ectopically generated by demyelinating lesions in the
cortico-spinal pathways induce tonic spasm which, in turn, induce ischemic muscle pain
Spasticity pain Mixed pain secondary to lesions in the central motor pathways but mediated by muscle
nociceptors
Other pains Psychogenic and overlapping pain
Pain in other illnesses not related to MS
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treatment are used, including the following: damaging certain
zones of the thalamus or DREZ (dorsal root entry zone) lesions
by microsurgically cutting the dorsal roots in the spinal entry
area. Today, these methods are being replaced with the
stimulation of speciﬁc structures of the nervous system [30,31].
6. Lhermitte's sign
Another type of central pain in MS is Lhermitte's sign, which is
usually observed in the initial stages of the disease and is more
frequently observed in patients with primary progressive MS
[8]. Al-Araji and Oger describe it as 'a transient short-lasting
sensation related to neck movement felt in the back of the
neck, lower back or in other parts of the body' [32]. It is a feeling
described as an 'electric shock', vibration and tingling lasting
less than 2 s, triggered by neck ﬂexion with immediate relief
upon cessation of the ﬂexion. It has been associated with
lesions in the posterior columns of the cervical spinal cord and
is thought to be caused by the hypersensitivity of demyeli-
nated cervical sensory axons to stretching. The prevalence of
Lhermitte's sign ranges from 9% to 16% during the period with
no relapses and approximately 40% during MS exacerbation
[3,7,32–35]. Fryze et al. observed this symptom in 26%
of patients [2]. In most cases, Lhermitte's sign remits within
4–6 weeks. The high frequency of central pain evident in
various subtypes of MS places it among the most frequent
symptoms of the disease [3,8,32–35].
The treatment of Lhermitte's phenomenon is similar to
that of other central neuropathic types of pain. One controlled
study showed a positive effect of intravenously injected
lidocaine and oral mexiletine [36].7. Painful tonic spasms (PTS)
Painful tonic spasms (PTS) are diagnosed in 11–15% of MS
patients [3,7,9,10]. The seizure-like, involuntary dystonic
spasms may be one- or two-sided and are usually brought on
by movement. Previously, they were referred to as 'painful
tonic seizures'. However, electroencephalography showed
that there were no epileptiform discharges during such an
episode; thus the term was abandoned [37]. The attacks are
often preceded by an aura. In addition to movement, they
are also brought on by touch, hyperventilation or emotions
[1,2,38]. They usually occur several times a day and last for
less than 2 min [1–3,38]. However, they may also occur at
night and disturb sleep. They usually have a stereotypical
course and can be chronic or recurrent, with repeated
episodes every several days or months. In some cases, the
pain directly precedes the spasm, which indicates that the
pain may not be caused by the muscle spasm itself.
Additionally, the spasms do not necessarily have to be
painful [1,2]. MRI showed lesions in the areas of basal
ganglia, internal capsule, cerebral peduncles, medulla and
spinal cord in patients with attacks of painful tonic spasms
[37]. It is postulated that the symptoms result from ephaptic
spreading of spontaneous discharges triggered by demyeli-
nated axons [37,38].
Painful tonic spasms may be managed with antiepileptic
drugs including carbamazepine, phenytoin and gabapentin, as
well as intravenous infusions of lidocaine [27,28]. Some
authors suggest injecting botulinum toxin [23,24]. Botulinum
toxin injections may also be used if a patient is suffering from
localized, focal spasticity. Injections are repeated every three
to four months.
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Musculoskeletal pain, also known as nociceptive pain, is the
most common pain in multiple sclerosis [3,4,11,15]. Nocicep-
tors are free nerve endings located in all types of body tissues,
except the brain, that detect stimuli and interpret them as
pain. This pain is caused by tissue damage detected by the
nociceptors, while neuropathic pain is related to nervous
system lesions [3]. Musculoskeletal pain is usually secondary
to muscular weakness, spasms, spasticity and imbalance. It is
most often seen in the hips, legs and arms and is most often
seen when muscles, tendons and ligaments remain immobile
for a long time.
Lower-back pain and neck pain can occur as a result of
irregular, asymmetric movement patterns and postures, and
changes in muscle strength, tone (spasticity) or length
(contracture). Pain associated with spasticity and muscle
spasms can include muscle aching, cramping or pulling [4].
These symptoms are often worse at night or early in the
morning [3].
The prevalence of low back pain is 10–20% [4,7,10,39]. The
observed prevalence depends upon the selected sample, but it
increases in older people. Asymmetric posture and difﬁculty in
ambulation can be predisposing factors to back pain. Lumbar
spasticity is also a possible cause of lower-back pain, due to
increased muscle tension and its effect on lumbar spine joints
[39].
It is postulated that pain within muscles and joints is
associated with musculoskeletal complaints; however, it may
also be a manifestation of central pain [5,12].
Secondary musculoskeletal pain can also be caused by the
drugs used to treat MS. Interferon beta frequently causes
muscular pain, while long-term steroid treatment may result
in osteoporosis and, consequently, vertebral compression
fractures [3,7,12].
Pharmacotherapy of musculoskeletal pain is usually
started with non-steroid anti-inﬂammatory drugs, which
bring the desired effect only at the initial stage of treatment.
The basic procedure in this case is physiotherapy aimed at
improving the stability of proximal muscles and teaching
individuals to maintain good posture while standing and
sitting. Electrotherapy, cryotherapy, magnotherapy and hy-
drotherapy belong to the most frequently used physical
methods [40,41]. Electrotherapy is mainly used in symptom-
atic treatments to treat pain and excessive spasticity.
9. Trigeminal neuralgia
Trigeminal neuralgia (TN) is most likely the best known
neuropathic pain syndrome in multiple sclerosis. It appears in
the trigeminal innervation area and is characterized by
paroxysms of shooting, piercing, stinging, 'electric-like' pain.
The pain has a sudden onset, is extremely strong and is often
accompanied by a characteristic facial grimace. It lasts from
several to several dozen seconds, exceptionally up to a few
minutes, and disappears. The pain may occur spontaneously
or be caused by stimuli in speciﬁc areas of the face or mouth. A
gentle touch or irritation of the so-called trigger zone causespain [42]. The risk of the appearance of the symptomatic TN
is 20 times higher in patients with multiple sclerosis than in
the general population [43]. Studies show that the preva-
lence of trigeminal neuralgia in patients with multiple
sclerosis falls in the range between 1.9% and 6.3% [10,12].
The clinical symptoms are the same as in the idiopathic
form, with no dysesthesia and the presence of points
triggering the paroxysms of pain. Neuralgia occurs most
often (in approximately 90% of patients) in the area of the V2
and V3 branches [44]. Post-mortem studies show that
trigeminal neuralgia in patients with multiple sclerosis is
related to demyelination plaques in the pons. Studies with
the use of MRI indicate one- or two-side demyelination
plaques in the course of nerve V [45]. High signal lesions
along the trigeminal nerve have been observed both in the
pons [44] and the brainstem nuclei [46]. Although it occurs
relatively rarely in patients with multiple sclerosis, trigemi-
nal neuralgia is very painful and has a signiﬁcant impact on
the patients' quality of life [47].
Glossopharyngeal neuralgia (a severe pain in the posterior
pharynx, tonsils and the base of the tongue) is extremely rare
in patients with MS [48].
Carbamazepine is the ﬁrst-line drug for the treatment of
trigeminal and glossopharyngeal neuralgia in the course
of multiple sclerosis, as in the case of the idiopathic forms
[45–48]. However, it can cause side effects, leading speciﬁcally
to a reversible exacerbation of multiple sclerosis symptoms
[49]. Alternatively, oxcarbazepine or lamotrigine and gaba-
pentin can be used [27,28].
10. Headaches
Worldwide, almost 50% of general population suffers from at
least one of the following types of headache: tension
headache, migraine, cluster headache or chronic daily
headache [50]. Therefore, it may be presupposed that head-
aches will also be more frequent in patients with MS. From the
neurological point of view, the MS-related inﬂammatory
demyelinating lesions may evoke headaches due to damage
of the pathways associated with the pathology of migraine,
tension-type headache (TTH) and trigemino-autonomic
cephalalgia.
The most recent studies (mainly prospective and case–
control ones) conducted in various countries according to the
Guidelines of the International Headache Society of 2004,
showed that the prevalence of TTH is similar in patients with
MS and in the control group (TTH was reported by 21–48% of
patients with MS) [51–53].
The relationship between the onset of MS and TTH was
assessed in one study [54]. Nearly two thirds of patients
experienced their ﬁrst headache before the onset of multiple
sclerosis [54]. Because headache generally precedes the onset
of MS and is not signiﬁcantly modiﬁed by the disease, it seems
that in most MS patients TTH may not be considered a reactive
or secondary disorder. One could agree with the hypothesis
that TTH, although not necessarily more frequent in patients
with multiple sclerosis than in healthy control group patients,
may be caused by demyelination damaging the tracks engaged
in TTH pathogenesis.
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sclerosis was suggested over half a century ago by Compston
and McAlpine [55], who reported that 2% of MS patients had
experienced migraine during the 3 months preceding the
onset of the disease. The results were later conﬁrmed in a
retrospective review of 1113 MS patients, 18 (1.6%) of whom
complained of a migraine attack preceding MS onset and 26 of
whom experienced headache during the aggravation of MS.
They frequently showed symptoms of a posterior fossa mass
lesion [56]. The coincidence of time between migraine and the
bout of multiple sclerosis suggests that migraine headaches
may be a secondary symptom in some MS patients.
A double-blind study with two control groups, conducted
before interferon therapy was introduced, showed that 21% of
MS patients had migraine compared to 10% in patients with
neurological diseases other than MS (control group) [57]. The
beginning of headaches preceded symptoms of MS by an
average of 7 years [57]. In addition, not all studies revealed a
higher prevalence of migraine in MS patients [58,59].
Studies using scans suggest a greater probability of engage-
ment of the brainstem and diencephalon structures in
migraine-suffering MS patients in comparison to those patients
who do not suffer from migraines [60,61]. Another study also
showed a greater frequency of gadolinium-enhanced lesions in
the brainstem of headache-suffering patients [62], which
indicates the potential participation of these structures in the
generation of migraines. On the other hand, no differences were
found in the number or distribution of T2 lesions or gadolinium-
enhanced lesions between the groups of multiple sclerosis
patients with and without migraine [63].
Available data indicate that the age of MS onset, the
duration of the disease and the degree of patient's disability
are similar in MS patients with and without migraines
[51,57,62,63]. On the other hand, most researchers [52,53,63],
though not all of them [54], report a correlation between
migraine and relapsing remitting multiple sclerosis. Women
are overrepresented in the MS-migraine group, in comparison
to the MS-no headache group [63].
The standard treatment for migraine and tension headache
is usually effective.
11. Pain in retrobulbar optic neuritis
Retrobulbar optic neuritis is the ﬁrst symptom of multiple
sclerosis in 20% of cases [64]. It is characterized by blurred
vision or the complete loss of vision. Color vision deﬁciency
and contrast sensitivity frequently decrease proportionally to
visual acuity loss. Visual ﬁeld defect (especially central
scotoma) is typical of optic neuritis [65]. The symptoms
subside suddenly, within 10–20 h. They are accompanied by
pain, in most cases originating from behind the eye and
frequently preceding the disturbances of visual acuity. Ninety
percent of patients with optic neuritis suffer from periocular
pain, which may be present before the onset of vision loss [66].
However, patients may not initially complain of pain. It may be
helpful to ask if the pain is associated with eye movements.
The pain may even involve the whole head and range from
moderate to severe. It usually accompanies the visual
symptoms (at least initially). MRI of the optic nerve revealslesions of demyelination of approximately 1 cm in diameter
within the course of the optic nerve (there may be several of
them) [67]. In two-thirds of cases, the lesions are located in the
retrobulbar section of the optic nerve. Rapid visual recovery
occurs within 2–3 weeks after the onset of symptoms and the
symptoms stabilize within several subsequent months [22].
Approximately 70–80% of patients experience a complete
recovery of vision. In the rest of the patients, color vision
deﬁciency and contrast sensitivity remain, while the visual
acuity is normal. A minority of patients may experience
permanent visual disturbances, including blindness.
First-line drugs for the treatment of pain in retrobulbar
optic neuritis are corticosteroids.
12. Psychogenic pain
The cause of psychogenic pain has not been established. It is
believed to be associated with emotional and behavioral
factors and is triggered by psychological factors, thus it tends
to be treated as central pain [6–8]. It may resemble any type of
organic pain, even if morphological changes that could cause
the pain are excluded. It is frequently associated with an
emotional conﬂict or psychosocial problems. Psychogenic pain
is also often associated with depression, sleeping disturbances
and fatigue syndrome [68,69]. As a consequence of the
persistent pain, the patient usually draws more attention
from family and healthcare providers. The origin of the
psychogenic pain is related to the transmission of impulses
from the limbic system responsible for emotions to the
brainstem nuclei, which consequently leads to trigeminal
vascular reﬂex causing vasogenic headaches and other pain-
related reﬂex phenomena [8]. Psychogenic pain may be local or
generalized. Local pain is closely limited, usually to one or
several small areas. It is frequently located at the surface of the
face or head. Generalized pain may involve the whole body,
half of it, or just one limb [3–9]. Its prevalence in multiple
sclerosis is highly individual and hard to assess.
13. Overlapping pain
Overlapping pain is a sum of the psychological reaction to pain
and the physical pain resulting from the illness or accompa-
nying it. It increases the patient's sense of illness and is
supposed to convince people around the patient of the
immense suffering he is going through and the seriousness
of the condition. This attitude is frequently used to pursue
certain claims or judicial decisions.
14. Other types of pain in MS
It should be borne in mind that a patient with multiple sclerosis
may also present with pain in internal organs (bladder infection,
gastrointestinal disturbances). Additionally, it must not be
presupposed that pain is always caused by MS because there
may be a different cause requiring independent treatment. The
adverse effects of the pharmacotherapy shouldalso be taken into
account. They may include the following: ﬂu-like symptoms,
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 2 7 2 – 2 7 9278headaches, muscular pain (interferon beta), tightness or pain in
the chest (glatiramer acetate) or glucocorticoid-induced osteo-
porosis with frequent vertebral compression fractures.
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